18:28 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Celyad’s CAR T leads to leukemia-free state in AML patient

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) said a patient with acute myelogenous leukemia (AML) achieved a morphologic leukemia-free state (MLFS) after receiving the company's chimeric antigen receptor (CAR) T cell therapy (CAR-T NKG2D, CAR-T NKR-2) in the...
23:00 , Aug 10, 2017 |  BC Week In Review  |  Company News

Celyad amends CAR T deal

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) amended a 2015 deal to increase its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC (Lebanon, N.H.) and Dartmouth College (Hanover, N.H.)....
23:20 , Aug 4, 2017 |  BC Extra  |  Company News

Celyad gains on CAR T deal amendment

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) amended a 2015 deal to increase its share of future revenues generated from chimeric antigen receptor (CAR) T assets partnered with Celdara Medical LLC (Lebanon, N.H.) and Dartmouth College (Hanover, N.H.)....
21:24 , May 11, 2017 |  BC Innovations  |  Translation in Brief

Going universal

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell...
02:37 , Feb 28, 2015 |  BC Extra  |  Financial News

Cardio3 raises EUR 31.7M

Cardio3 BioSciences S.A. (Euronext:CARD) raised EUR 31.7 million ($36 million) through the sale of 713,380 shares at EUR 44.50 in a private placement with undisclosed institutional investors in the U.S. and Europe. UBS was the...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Celdara Medical, Virtici, Daiichi Sankyo deal

The companies partnered to jointly investigate therapeutic candidates to strengthen Daiichi's pipeline in oncology and additional undisclosed therapeutic areas. Daiichi said the partners may jointly develop compounds until proof of concept, and Daiichi will have...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Driving CAR-based cellular therapies

Adoptive T cell therapies were first developed in the mid-1980s but only recently entered the limelight owing to dramatic clinical results achieved with the latest incarnation, chimeric antigen receptor-based cell therapies. Novartis AG 's 2012...